EZH2 and sarcoma: Two of the eight genes identified in this in silico analysis (AURKA and EZH2) were targets for specific pharmacological inhibitors: the AURKA inhibitor alisertib under testing in clinical trials [83] and the EZH2 inhibitor tazemetostat, which is FDA approved for subsets of sarcoma and lymphoma patients, respectively.